A5004522280- Thyroid Cancer Diagnosis and Treatment
- Thyroid Disorders and Treatments
- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- HIV/AIDS Research and Interventions
- Bone health and treatments
- Thyroid and Parathyroid Surgery
- Bone health and osteoporosis research
- Head and Neck Anomalies
- BRCA gene mutations in cancer
- Pneumocystis jirovecii pneumonia detection and treatment
- Patient-Provider Communication in Healthcare
- Tuberculosis Research and Epidemiology
- HIV Research and Treatment
- Hypothalamic control of reproductive hormones
- Ophthalmology and Eye Disorders
- Estrogen and related hormone effects
- Neuroendocrine Tumor Research Advances
- Salivary Gland Tumors Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Reproductive Health and Contraception
- HIV, Drug Use, Sexual Risk
- Parathyroid Disorders and Treatments
- Clinical practice guidelines implementation
- HIV/AIDS Impact and Responses
Massachusetts General Hospital
2014-2024
St. Mary’s Hospital
2011-2023
Harvard University
2011-2023
Western University
2021-2022
Pfizer (United States)
2004-2016
Harvard University Press
1998-2015
Pfizer (United Kingdom)
2013
Florida College
2013
University of Florida
2013
Hasbro Children's Hospital
2013
Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis is influenced by coexisting medical conditions patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist subspecialty physicians others providing care patients with this condition. Methods: The American Thyroid Association (ATA) previously cosponsored were...
Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis is influenced by coexisting medical conditions patient preference. This article describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist subspeciality physicians others providing care patients with this condition.The development these was commissioned American Thyroid Association in association...
This analysis was performed to determine the effect of initial therapy on outcomes thyroid cancer patients. The study setting a prospectively followed multi-institutional registry. Patients were stratified as low risk (stages I and II) or high III IV). Treatments employed included near-total thyroidectomy, administration radioactive iodine, hormone suppression therapy. Outcome measures overall survival, disease-specific disease-free survival. Near-total aggressive each independently...
Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after hormone withdrawal. The objectives this study were compare effect administered recombinant with withdrawal on results radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels. Two hundred twenty-nine adult patients differentiated cancer requiring WBS studied. Radioiodine Tg measurements performed...
To detect recurrent disease in patients who have had differentiated thyroid cancer, periodic withdrawal of hormone therapy may be required to raise serum thyrotropin concentrations stimulate tissue so that radioiodine (iodine-131) scanning can performed. However, causes hypothyroidism. Administration recombinant human stimulates without requiring the discontinuation therapy.
BACKGROUND A novel prognostic staging classification encompassing all forms of thyroid carcinoma was created for the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) Registry, with goal prospective validation and comparison other available classifications. METHODS Patient information recorded prospectively from 14 institutions. Clinicopathologic based on patient age at diagnosis, tumor histology, size, intrathyroidal multifocality, extraglandular invasion, metastases,...
Background: Approximately 15% more patients taking levothyroxine (LT4) report impaired quality of life compared to controls. This could be explained by additional diagnoses independently affecting and complicating assignment causation. study sought investigate the underpinnings reduced in hypothyroid provide data for discussion at a symposium addressing hypothyroidism. Methods: An online survey was posted on American Thyroid Association Web site forwarded multiple groups. Respondents were...
The ideal therapy for differentiated thyroid cancer is uncertain. Although hormone treatment pivotal, the degree of thyrotropin (TSH) suppression that required to prevent recurrences has not been studied in detail. We have examined relation TSH baseline disease characteristics and likelihood progression a cohort patients who followed multicenter registry was established 1986. present study describes 617 with papillary 66 follicular annually median 4.5 years (range 1-8.6 years). Cancer...
Background. Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits antiretroviral therapy in resource-limited settings. The prevalence was assessed among patients from KwaZulu Natal, South Africa, following failure their first highly active (HAART) regimen. Methods. Genotypic testing performed on plasma samples who experienced virologic HAART regimen at 2 clinics Natal. Clinical and demographic data were obtained medical records. Regression analysis...
Current diagnostic studies [radioiodine uptake and serum thyroglobulin (Tg) levels] for residual or metastatic thyroid tissue in patients with differentiated carcinoma require a hypothyroid status necessary adequate endogenous TSH stimulation. However, almost all have symptoms of clinical hypothyroidism during this period. As shown the present study, recombinant human (rhTSH) allows stimulation 131I Tg release from euthyroid patients. To assess safety, dosage, preliminary efficacy,...
Despite very low mortality associated with micropapillary thyroid cancer, locoregional recurrence is common and controversy exists regarding optimal surgical treatment the role of adjunctive radioiodine.The National Thyroid Cancer Treatment Cooperative Study Group Registry was analyzed for recurrences in patients unifocal versus multifocal or without nodal disease, depending upon extent surgery use radioiodine. Six hundred eleven considered disease-free after initial therapy were followed...
Although loss to follow-up after antiretroviral therapy (ART) initiation is increasingly recognized, little known about pre-treatment losses care (PTLC) an initial positive HIV test. Our objective was determine PTLC in newly identified HIV-infected individuals South Africa.We assembled the African Test, Identify and Link (STIAL) Cohort of persons presenting for testing at two sites offering CD4 count Durban, Africa. We defined as failure have a within 8 weeks diagnosis. performed...
To determine the efficacy of gefitinib in patients with advanced thyroid cancer.In this open-label phase II trial, 27 radioiodine-refractory, locally advanced, or metastatic cancer were treated 250 mg daily gefitinib. Histologic subtypes included papillary (41%), follicular (22%), anaplastic (19%), medullary (15%), and Hürthle cell carcinomas (4%). The primary endpoint was overall response rate. Secondary endpoints toxicity, progression-free survival (PFS), (OS).There no objective responses...
Thyroid cancer predominately affects women, carries a worse prognosis in older age, and may have higher mortality men. Superimposed on these observations is the fact that most women attained menopause by age 55 yr.The objective of study was to determine whether men contribute disproportionately papillary thyroid (PTC) or PTC prognosis.Gender-specific normalized using age-matched subjects from U.S. population. Multivariate Cox proportional hazard regression models incorporating gender,...
Treatment of differentiated thyroid cancer has been studied for many years, but the benefits extensive initial surgery and addition radioiodine therapy or external radiation remain controversial.To determine relations among extent surgery, therapy, in treatment high-risk papillary non-Hürthle-cell follicular carcinoma.Analysis data from a multicenter study.14 institutions United States Canada participating National Thyroid Cancer Cooperative Study Registry.385 patients with (303 carcinoma 82...
Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal.Our objective was to examine the impact of short-term hypothyroidism on health-related quality life (HRQOL) patients after rhTSH vs. withdrawal.In...
Context: Initial treatments for patients with differentiated thyroid cancer are supported primarily by single-institution, retrospective studies, limited follow-up and low event rates. We report updated analyses of long-term outcomes after treatment in cancer. Objective: The objective was to examine effects initial therapies on outcomes. Design/Setting: This a prospective multi-institutional registry. Patients: A total 4941 patients, median follow-up, 6 years, participated. Intervention:...
Serum thyrotropin (TSH) concentration and thyroid autoimmunity may be of prognostic importance in differentiated cancer (DTC). Preoperative serum TSH level has been associated with higher DTC stage cross-sectional studies; data are contradictory on the significance at time diagnosis.We sought to assess whether preoperative perioperative antithyroglobulin antibodies (TgAb) were outcome patients followed by National Thyroid Cancer Treatment Cooperative Study, a large multicenter...